Finerenone

🧮 Dose calculator

Diabetic nephropathy · Regimen source: FDA Kerendia · 2.2, Table 1FDA Kerendia · 2.3

• • Check potassium before starting: do not start if >5.0. Increase to 20 mg after 4 weeks per potassium and eGFR. eGFR <25: initiation not recommended. FDA Kerendia · 2.1FDA Kerendia · 2.3

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Kerendia · 8.1

  “Risk Summary There are no available data on Kerendia use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Kerendia · 8.2

  “Risk Summary There are no data on the presence of finerenone or its metabolite in human milk, the effects on the breastfed infant or the effects of the drug on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Kerendia · 8.4

  “The safety and efficacy of Kerendia have not been established in patients below 18 years of age.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Kerendia · 8.5

  “No dose adjustment is required.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.